In patients with metastatic NSCLC and progression on or after platinum-containing chemotherapy, pembrolizumab is approved for the treatment of patients with tumour PD-L1 expression ≥1% based on results from the KEYNOTE-010 (NCT01905657) study [4]. Here, CD274 is linked to non-small cell lung carcinoma.